95 results
Page 2 of 5
8-K
EX-99.1
0l3pwwa 1kx
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.1
9go5 zsoq
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
hp4fbbg10ase3aodv
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
dfx0gbge757dk
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
t184hqpo
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
EX-99.1
5fiwvd 7c6w
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
EX-99.1
ixkjhzgx4jk
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
EX-99.1
89xw2e95w7byab89a2f6
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
gj6efl
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
r5zjm6ln
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
wp37q kjwm
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
uainxr3a jp
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
06x35k9 4x8aheg522hy
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
0l1oldubu06sj8e0d54
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-99.1
tmkarzg6
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
fuqdb 3u8
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
xoct50
17 Apr 23
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
11:09am